will bispecific antibodies challenge car t-cell therapy in follicular lymphoma? - medpage today
Published 2 years ago • 453 plays • Length 6:59Download video MP4
Download video MP3
Similar videos
-
5:44
lemzoparlimab promising in tough-to-treat lymphoma - medpage today
-
1:40
current & future outlooks on car-t therapy & bispecific antibodies in follicular lymphoma
-
6:23
the benefits of bispecific antibodies over car-t cell therapy in lymphoma
-
4:09
finally, a positive study in first-line dlbcl treatment. what will it mean? - medpage today
-
1:23
advantages of bispecific antibodies over car-t therapy in lbcl
-
1:15
the role of bispecific antibodies in the treatment of r/r large b-cell lymphoma
-
2:37
efficacy of bispecific cd19/cd22 car t-cells in b-cell malignancies
-
2:03
the next generation of novel agents in development for aggressive b-cell lymphoma
-
1:30
bispecific antibodies for r/r aggressive b-cell lymphomas
-
12:15
car-t vs bispecific antibodies for lymphoma
-
1:29
cd5.car t-cell therapy in patients with t-cell lymphoma
-
3:39
updates on car t-cells in lymphoma
-
4:35
bispecific antibodies vs car t-cells for r/r multiple myeloma
-
2:43
bispecific antibodies for non-hodgkin lymphoma
-
2:43
long-term follow-up results of zuma-5: axi-cel in patients with r/r indolent nhl
-
2:40
phase ii study of glofitamab in patients with r/r lbcl
-
2:22
combining car-ts & bispecific antibodies
-
6:40
car-t vs bispecifics: the best immune approach to replace asct
-
1:39
dr hu on choosing between bispecific antibodies vs car t-cell therapy in dlbcl